Related Experiment Videos
[Ciprofloxacin treatment in bacterial skin infections]
Abstract:
In a controlled bacteriological study, the effectiveness and tolerance of ciprofloxacin was investigated in 61 patients with extensive bacterial skin infections. The pathogens found, all of which were sensitive to ciprofloxacin, were, for the most part, Staphylococcus aureus and hemolytic streptococci. Ciprofloxacin was administered at a daily oral dose of 2 x 500 mg for an average of 12 days. Primary elimination of the pathogen was achieved in 96 per cent of the patients, in 4 per cent there was a marked reduction in in vitro pathogen growth. Clinical healing or improvement was observed in 98.3 per cent of the patients. Treatment with ciprofloxacin was very well tolerated. No changes in the laboratory parameters, blood count, alkaline phosphatase, creatinine, urea, SGOT, SGPT or urinary status were observed. By way of undesired side effects, transient diarrhea occurred in only a single patient. The results of this study demonstrate the considerable therapeutic value of ciprofloxacin in the treatment of bacterial skin infections.
Insights
Ciprofloxacin effectively treated extensive bacterial skin infections caused by Staphylococcus aureus and hemolytic streptococci in 61 patients. The antibiotic demonstrated excellent tolerance with minimal side effects, showing significant pathogen elimination and clinical improvement.
Area of Science:
- Bacteriology
- Dermatology
- Pharmacology
Context:
- Bacterial skin infections pose a significant clinical challenge.
- Staphylococcus aureus and hemolytic streptococci are common causative agents.
- Evaluating novel therapeutic options is crucial for effective treatment.
Purpose:
- To assess the efficacy and safety of ciprofloxacin in treating extensive bacterial skin infections.
- To determine the microbiological and clinical outcomes of ciprofloxacin therapy.
- To evaluate the tolerability and side effect profile of ciprofloxacin.
Summary:
- A controlled study involved 61 patients with bacterial skin infections, primarily caused by ciprofloxacin-sensitive Staphylococcus aureus and hemolytic streptococci.
- Patients received oral ciprofloxacin (2 x 500 mg daily) for an average of 12 days.
- High pathogen elimination rates (96%) and clinical improvement (98.3%) were observed, with excellent tolerability and minimal adverse effects like transient diarrhea.
Impact:
- Ciprofloxacin demonstrates significant therapeutic value for bacterial skin infections.
- The findings support the use of ciprofloxacin as a well-tolerated and effective treatment option.
- This study contributes to evidence-based guidelines for managing bacterial dermatological conditions.